UNLABELLED: Fructose consumption predicts increased hepatic fibrosis in those with nonalcoholic fatty liver disease (NAFLD). Because of its ability to lower hepatic adenosine triphosphate (ATP) levels, habitual fructose consumption could result in more hepatic ATP depletion and impaired ATP recovery. The degree of ATP depletion after an intravenous (IV) fructose challenge test in low- versus high-fructose consumers was assessed. We evaluated diabetic adults enrolled in the Action for Health in Diabetes Fatty Liver Ancillary Study (n = 244) for whom dietary fructose consumption estimated by a 130-item food frequency questionnaire and hepatic ATP measured by phosphorus magnetic resonance spectroscopy and uric acid (UA) levels were performed (n = 105). In a subset of participants (n = 25), an IV fructose challenge was utilized to assess change in hepatic ATP content. The relationships between dietary fructose, UA, and hepatic ATP depletion at baseline and after IV fructose challenge were evaluated in low- (<15 g/day) versus high-fructose (≥ 15 g/day) consumers. High dietary fructose consumers had slightly lower baseline hepatic ATP levels and a greater absolute change in hepatic α-ATP/ inorganic phosphate (Pi) ratio (0.08 versus 0.03; P = 0.05) and γ-ATP /Pi ratio after an IV fructose challenge (0.03 versus 0.06; P = 0.06). Patients with high UA (≥ 5.5 mg/dL) showed a lower minimum liver ATP/Pi ratio postfructose challenge (4.5 versus 7.0; P = 0.04). CONCLUSIONS: High-fructose consumption depletes hepatic ATP and impairs recovery from ATP depletion after an IV fructose challenge. Subjects with high UA show a greater nadir in hepatic ATP in response to fructose. Both high dietary fructose intake and elevated UA level may predict more severe hepatic ATP depletion in response to fructose and hence may be risk factors for the development and progression of NAFLD.
UNLABELLED: Fructose consumption predicts increased hepatic fibrosis in those with nonalcoholic fatty liver disease (NAFLD). Because of its ability to lower hepatic adenosine triphosphate (ATP) levels, habitual fructose consumption could result in more hepatic ATP depletion and impaired ATP recovery. The degree of ATP depletion after an intravenous (IV) fructose challenge test in low- versus high-fructose consumers was assessed. We evaluated diabetic adults enrolled in the Action for Health in Diabetes Fatty Liver Ancillary Study (n = 244) for whom dietary fructose consumption estimated by a 130-item food frequency questionnaire and hepatic ATP measured by phosphorus magnetic resonance spectroscopy and uric acid (UA) levels were performed (n = 105). In a subset of participants (n = 25), an IV fructose challenge was utilized to assess change in hepatic ATP content. The relationships between dietary fructose, UA, and hepatic ATP depletion at baseline and after IV fructose challenge were evaluated in low- (<15 g/day) versus high-fructose (≥ 15 g/day) consumers. High dietary fructose consumers had slightly lower baseline hepatic ATP levels and a greater absolute change in hepatic α-ATP/ inorganic phosphate (Pi) ratio (0.08 versus 0.03; P = 0.05) and γ-ATP /Pi ratio after an IV fructose challenge (0.03 versus 0.06; P = 0.06). Patients with high UA (≥ 5.5 mg/dL) showed a lower minimum liver ATP/Pi ratio postfructose challenge (4.5 versus 7.0; P = 0.04). CONCLUSIONS: High-fructose consumption depletes hepatic ATP and impairs recovery from ATP depletion after an IV fructose challenge. Subjects with high UA show a greater nadir in hepatic ATP in response to fructose. Both high dietary fructose intake and elevated UA level may predict more severe hepatic ATP depletion in response to fructose and hence may be risk factors for the development and progression of NAFLD.
Authors: S E Perez-Pozo; J Schold; T Nakagawa; L G Sánchez-Lozada; R J Johnson; J López Lillo Journal: Int J Obes (Lond) Date: 2009-12-22 Impact factor: 5.095
Authors: Manal F Abdelmalek; Ayako Suzuki; Cynthia Guy; Aynur Unalp-Arida; Ryan Colvin; Richard J Johnson; Anna Mae Diehl Journal: Hepatology Date: 2010-06 Impact factor: 17.425
Authors: Stephen H Caldwell; Luiz Antonio R de Freitas; Sang H Park; Maria Lucia V Moreno; Jan A Redick; Christine A Davis; Barbee J Sisson; James T Patrie; Helma Cotrim; Curtis K Argo; Abdullah Al-Osaimi Journal: Hepatology Date: 2009-06 Impact factor: 17.425
Authors: Julia Szendroedi; Marek Chmelik; Albrecht Ingo Schmid; Peter Nowotny; Attila Brehm; Martin Krssak; Ewald Moser; Michael Roden Journal: Hepatology Date: 2009-10 Impact factor: 17.425
Authors: Mara Z Vitolins; Andrea M Anderson; Linda Delahanty; Hollie Raynor; Gary D Miller; Connie Mobley; Rebecca Reeves; Monica Yamamoto; Catherine Champagne; Rena R Wing; Elizabeth Mayer-Davis Journal: J Am Diet Assoc Date: 2009-08
Authors: Pietro Cirillo; Michael S Gersch; Wei Mu; Philip M Scherer; Kyung Mee Kim; Loreto Gesualdo; George N Henderson; Richard J Johnson; Yuri Y Sautin Journal: J Am Soc Nephrol Date: 2009-01-21 Impact factor: 10.121
Authors: Thomas Jensen; Manal F Abdelmalek; Shelby Sullivan; Kristen J Nadeau; Melanie Green; Carlos Roncal; Takahiko Nakagawa; Masanari Kuwabara; Yuka Sato; Duk-Hee Kang; Dean R Tolan; Laura G Sanchez-Lozada; Hugo R Rosen; Miguel A Lanaspa; Anna Mae Diehl; Richard J Johnson Journal: J Hepatol Date: 2018-02-02 Impact factor: 25.083
Authors: Irene Marco-Rius; Cornelius von Morze; Renuka Sriram; Peng Cao; Gene-Yuan Chang; Eugene Milshteyn; Robert A Bok; Michael A Ohliger; David Pearce; John Kurhanewicz; Peder E Z Larson; Daniel B Vigneron; Matthew Merritt Journal: Magn Reson Med Date: 2016-11-17 Impact factor: 4.668
Authors: Miguel A Lanaspa; Laura G Sanchez-Lozada; Yea-Jin Choi; Christina Cicerchi; Mehmet Kanbay; Carlos A Roncal-Jimenez; Takuji Ishimoto; Nanxing Li; George Marek; Murat Duranay; George Schreiner; Bernardo Rodriguez-Iturbe; Takahiko Nakagawa; Duk-Hee Kang; Yuri Y Sautin; Richard J Johnson Journal: J Biol Chem Date: 2012-10-03 Impact factor: 5.157
Authors: J S Sullivan; M T Le; Z Pan; C Rivard; K Love-Osborne; K Robbins; R J Johnson; R J Sokol; S S Sundaram Journal: Pediatr Obes Date: 2014-06-24 Impact factor: 4.000